Cargando…

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas

BACKGROUND: Patients with pancreatic ductal adenocarcinoma (PDAC) have late diagnosis which results in poor prognosis. Currently, surgical resection is the only option for curative intent. Identifying high-risk features for patients with aggressive PDAC is essential for accurate diagnosis, prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehta, Shreya, Bhimani, Nazim, Gill, Anthony J., Samra, Jaswinder S., Sahni, Sumit, Mittal, Anubhav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287202/ https://www.ncbi.nlm.nih.gov/pubmed/34290990 http://dx.doi.org/10.3389/fonc.2021.708963

Ejemplares similares

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single‐cell analysis
por: Byeon, Sooin, et al.
Publicado: (2023)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2020)

Drain fluid biomarkers for prediction and diagnosis of clinically relevant postoperative pancreatic fistula: A narrative review
por: Rykina-Tameeva, Nadya, et al.
Publicado: (2022)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis
por: Stephenson, David, et al.
Publicado: (2017)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Drain fluid biomarkers for the diagnosis of clinically relevant postoperative pancreatic fistula: a diagnostic accuracy systematic review and meta-analysis
por: Rykina-Tameeva, Nadya, et al.
Publicado: (2023)

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma
por: Tayao, Michael, et al.
Publicado: (2016)

Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma
por: Xu, Xinsen, et al.
Publicado: (2023)

Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
por: Zhao, Juan, et al.
Publicado: (2022)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
por: Mehta, Shreya, et al.
Publicado: (2015)

The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients’ survival
por: Jambor, Maxwell A., et al.
Publicado: (2022)

Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis
por: Maloney, Sarah, et al.
Publicado: (2021)

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma
por: d’Engremont, Christelle, et al.
Publicado: (2021)

Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma
por: Huang, Xinyang, et al.
Publicado: (2022)

Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma
por: Fang, Lishan, et al.
Publicado: (2023)

Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
por: Gillson, Josef, et al.
Publicado: (2022)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma
por: Gao, Yuzhen, et al.
Publicado: (2020)

Granular cell tumour of the pancreas: a case report and systematic review
por: Tree, Kevin, et al.
Publicado: (2023)

Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Kim, Hongbeom, et al.
Publicado: (2020)

The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

Postoperative pancreatic fistula: a review of traditional and emerging concepts
por: Nahm, Christopher B, et al.
Publicado: (2018)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma
por: Yang, Sen, et al.
Publicado: (2022)

Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma
por: Li, Haoran, et al.
Publicado: (2021)

Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma
por: Khan, Imteyaz Ahmad, et al.
Publicado: (2021)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
por: Wu, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9ndugapffvb6sfbhbp1efnm4ri